An umbrella review and meta‐analysis of renin–angiotensin system drugs use and <scp>COVID</scp> ‐19 outcomes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An umbrella review and meta‐analysis of renin–angiotensin system drugs use and COVID ‐19 outcomes

Published:2022-10-19 Issue:2 Volume:53 Page:
ISSN:0014-2972
Container-title:European Journal of Clinical Investigation
language:en
Short-container-title:Eur J Clin Investigation

Author:

Kurdi Amanj¹²³^ORCID,Mueller Tanja¹,Weir Natalie¹

Affiliation:

1. Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde Glasgow Scotland UK

2. Department of Pharmacology and Toxicology College of Pharmacy, Kurdistan Region Government, Hawler Medical University Erbil Iraq

3. Division of Public Health Pharmacy and Management School of Pharmacy, Sefako Makgatho Health Sciences University Pretoria South Africa

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/eci.13888

Reference78 articles.

1. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study

2. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

3. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety

4. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients

5. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Renin-Angiotensin-Aldosterone System Blockers on Adverse Outcomes in COVID-19 Patients;Cardiology;2024-07-22

2. Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient;Inflammopharmacology;2024-04-15

3. Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients;Heliyon;2023-09

4. COVID-19 and metabolic syndrome;Best Practice & Research Clinical Endocrinology & Metabolism;2023-07

5. Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review;Biomedicines;2023-04-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3